drugset / Trial / NCT04370704
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.
Timeline
- Start
- 2020-07-27
- Primary completion
- 2025-08-25
- Completion
- 2025-08-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retifanlimab | Monoclonal antibody | — | Intravenous |
| Subject | Tuparstobart | Monoclonal antibody | — | Intravenous |
| Subject | Verzistobart | Monoclonal antibody | — | Intravenous |